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To improve further the patency rate of infarct-related 
Sixty minutes after the start of infusion, 54 (74%) of 73 
coronary arteries, the following accelerated dosage regimen 
of recombinant tissue-type plasminogen activator W-PA) 
was administered to 80 patients with acute myocardial 
infarction of 16 h duration: 15 mg intravenous bolus, 50 
mg infusion over 30 min and 35 mg infusion over the 
following 60 min. After coronary angiography at 90 min 
coronary angioplasty was performed in 16 patients and 
additional thrombolysis in 3 patients. Six patients were not 
included in the final angiographic analysis, mostly because 
of borderline ST segment elevations, in order to avoid 
overestimation of the efficacy of this dose regimen. Four of 
these had a patent infarct artery; no early angiogram was 
performed on two. 
Within the last few years a number of large, controlled 
clinical trials (l-4) have shown that thrombolytic therapy 
reduces mortality after acute myocardial infarction. This 
result is generally accepted to be a consequence of the 
recanalization of the infarct-related coronary artery. Patency 
rates between 55% and 75% have been reported, the higher 
values being obtained with recombinant tissue-type plasmin- 
ogen activator (rt-PA) (5-10). 
Because of the positive correlation between thrombolytic 
efficacy and infusion rate of rt-PA (11,12), we hypothesized 
that the recanalization rate of initially occluded coronary 
arteries could be increased and the time to reperfusion 
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patients had a patent infarct-related artery (Thrombolysis 
in Myocardial Infarction [TIMI] grade 2 or 3) as did 67 
(91%) of 74 patients at 90 min. At 24 h, 61 (92.4%) of 66 
patients showed a patent infarct artery. Recurrent myocar- 
dial ischemia was noted in 12 patients, 7 (9.4%) of whom 
experienced reinfarction during the hospital stay. Minor 
local bleeding complications were observed in 14 patients 
(17.5%). There were four in-hospital cardiac deaths; one 
patient who underwent additional thrombolysis for recur- 
rent ischemia died from bleeding complications. 
(J Am Co11 Cardiol1989;14:1566-9) 
These results show that a rapid infusion of 100 mg of 
&PA over 90 min yields a high early patency rate of the 
infarct-related artery without an increase in reocclusion 
rate and adverse reactions. 
shortened by administering the recommended dose of 100 
mg within 90 min rather than 3 h. 
Methods 
Study patients. Between June 1987 and June 1988, 80 
patients with acute myocardial infarction diagnosed 56 h 
after symptom onset by ST elevation in at least two electro- 
cardiographic (ECG) leads (21 mm in standard leads or 22 
mm in precordial leads) and between the ages of 25 and 75 
(57 f 10) years were included in the trial. Sixty-seven were 
men and 13 women. The myocardial infarction was anterior 
in 39 and inferior in 41 patients. The mean time between 
onset of symptoms and the start of rt-PA infusion was 150 2 
26 min. 
All patients received 5000 IU of heparin as an intravenous 
bolus before entering the trial. After informed consent had 
been obtained, a 15 mg rt-PA (Actilyse, Dr. Karl Thomae, 
GmbH) intravenous bolus injection was given followed by an 
intravenous infusion of 50 mg of rt-PA over 30 min and a 
further 35 mg over the following 60 min. During the infusion 
period the patient was transferred to the catheterization 
laboratory and the first angiogram of the infarct-related 
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Table 1. Angiography and Interventions in 80 Patients 
Patients 
NO. % 
Total no. of patients 
60 min angiogram 
90 min angiogram 
No. of finally included patients 
60 min angiogram 
90 min angiogram 
Intervention5 
PTCA 
12 to 36 h angiogram 
Interventions 
PTCA 
Coronary bypass surgery 
14 to 21 days angiogram 
Interventions 
PTCA 
Coronary bypass surgery 
80 
77180 96 
78180 98 
74 
73174 99 
74!74 I 00 
13 
66174 89 
9 
2 
58174 78 
PICA = percutaneous transluminal coronary angioplasty 
coronary artery was performed 60 min after the start of 
infusion. After angiography of the other coronary arteries 
the angiogram of the infarct-related artery was repeated at 90 
min. After the 90 min coronary angiogram, the possibility of 
further interventions was left to the discretion of the inves- 
tigator. 
Angiographic evaluation of the infarct-related artery was 
repeated between 12 and 36 h after rt-PA infusion; coronary 
angiography and ventriculography were again repeated be- 
tween 14 and 21 days after therapy with rt-PA. The patency 
of the infarct-related artery was assessed centrally from the 
coronary arteriograms according to the criteria of the 
Thrombolysis in Myocardial Infarction (TIMI) Study Group 
(13). 
Serum creatine kinase-MB was analyzed at 4 h intervals 
until 48 h. Hemostatic variables were analyzed in plasma 
samples taken at baseline and at 90 min, 24 h and 48 h after 
treatment. Intravenous heparin at therapeutic levels was 
given at least until day 4, followed by subcutaneous heparin 
or oral anticoagulation. 
60 minutes 
Figure 1. Coronary angiographic find- 
ings of infarct-related artery at 60 
min, 90 min and 24 h in 74 patients. 
TIM1 011 = no or only minimal filling; 
TIMI 2 == open vessel with delayed 
distal filling; TIMI 3 = open vessel 
with prompt distal filling. 
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Results 
Coronary angiographic findings. Among the 80 patients 
included in the study, a 60 min angiogram was available in 77 
and a 90 min angiogram in 78 (Table 1). To avoid overesti- 
mation of the efficacy of treatment in this uncontrolled 
study, six patients were excluded from the final angiographic 
evaluation for the following reasons: four patients had only 
borderline ST elevation as judged by the central evaluation 
of the ECG at entry; one of these died before angiography 
and the other three had patent coronary arteries. In another 
patient with patent coronary arteries, the infarct-related 
artery could not be identified. One patient aged 24 years did 
not undergo early angiography because of acute left ventric- 
ular failure and resuscitation. Because no significant coro- 
nary artery lesion was detected in the 3 week coronary 
angiogram, a severe myopericarditis was suspected, al- 
though the initial ST segment elevation of 47 mm in the 
anterior leads resolved almost completely within 24 h. 
In 73 of the finally included 74 patients the first angiogram 
was performed 60 min after the start of the infusion. Forty- 
three (59%) had an open infarct-related coronary artery with 
prompt distal filling (TIM1 grade 3). I1 (15%) had an open 
vessel with delayed peripheral perfusion (TIM1 grade 2) and 
19 (26%) had no or only minimal perfusion (TIM1 grade 0 or 
1). After 90 min, angiography was performed in all of the 74 
included patients. The infarct-related artery was fully per- 
fused (TIM1 grade 3) in 58 patients (78%), and there was 
delayed perfusion (TIM1 grade 2) in 9 patients (12%); only 7 
patients showed an occluded artery (TIM1 grade 0 or 1). 
Coronary angioplasty was performed in five of the seven 
patients with an occluded infarct-related artery; it was 
successful in four cases. Eight patients with an open infarct- 
related artery at 90 min also underwent coronary angio- 
plasty. 
In the third angiographic study, performed in 66 patients 
between 12 and 36 h after the start of the therapy, an open 
infarct-related coronary artery (TIM1 grade 2 or 3) was found 
in 61 patients (92%) (Fig. 1, Table 2). 
Reocclusion, reinfarction and mortality. A total of 12 
patients demonstrated clinical signs of recurrent ischemia. 
Five of these did not develop reinfarction (symptoms and 
24 hours 
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Table 2. Patency 
in 74 Patients 
Time of 
Angiography 
60 min 
90 min 
24 (212) h 
14 to 28 days 
Rates of Infarct-Related Arteries 
Patency Grade (95% confidence intervals) 
TIMI 2 TIMI 3 TIM1 2 t 3 
7X&25.4% 46.8%-70.3% 62.4%-83.5% 
5.7%21.8% 67.37&87.1% 81.5%96.1% 
0.9%12.7% 77.5%-94.6% 83.2%97.5% 
0.00&4% 75.9%-94.8% 75.9%94.8% 
*TIMI 2 = open vessel with delayed peripheral filling; TIMI 3 = open 
vessel with prompt distal filling. 
new Q waves or CK MB elevation > twice normal); one had 
coronary angioplasty, two intravenous thrombolysis and two 
had no intervention. 
The reinfarction rate up to 48 h was 8% (6 of 74). One 
further patient developed reinfarction after 48 h, yielding a 
reinfarction of 9% during the hospital stay. 
Angiographically confirmed reocclusion within 48 h after 
the start of the infusion was found in 7 (11%) of the 67 
patients with an open infarct-related artery at the 90 min 
angiogram. One of these reocclusions was not accompanied 
by symptoms of reischemia. Four patients died from cardio- 
genie shock and one patient from bleeding complications. 
Bleeding complications. Three major bleeding complica- 
tions were encountered in this study. The woman who died 
from generalized bleeding complications was found to have a 
bleeding disorder before the start of thrombolysis. During 
the rt-PA infusion a puncture of the vena jugularis interna 
was performed whereby the carotid artery was injured 
leading to an extensive hematoma. Because of recurrent 
angina, additional thrombolysis with another thrombolytic 
agent was performed. However the patient’s condition could 
not be stabilized and she died. Suspected cerebral bleeding 
was not confirmed because neither computed tomography 
nor an autopsy was performed. 
One patient developed abdominal pain 2 days after throm- 
bolysis. Bleeding into a liver cyst was suggested by sonog- 
raphy, but the further clinical course did not necessitate any 
specific treatment. One patient had epistaxis after nasal 
intubation. Fourteen patients (18%) had prolonged bleeding 
or hematoma at the arterial puncture site. 
Hemostatic findings. Degradation of circulating fibrin- 
ogen was comparable to that found in the German Activator 
Table 3. Comparison of Fibrinogen Values Between Regimens 
of 70 mg Over 90 Min (GAUS [6]) and 100 mg Over 90 Min 
(present study) 
Before infusion 
After 90 min 
After 24 h 
70 mg 
Dose 
3.2 2 1.1 
2.1 ? 0.9 
2.7 + 1.0 
No. of 
Patients 
115 
110 
112 
100 mg 
Dose 
3.1 + 1.1 
1.8 c 1.0 
2.2 + 0.9 
No. of 
Patients 
71 
70 
69 
Urokinase Study (GAUS) (6); our study shows no signifi- 
cantly increased fibrinogen degradation despite the increase 
of dosage from 70 to 100 mg within 90 min (Table 3). The 
fibrinogen level at 90 min was below 1 g/liter in 17 (23%) of 
the 74 patients. In the GAUS study (6), the fibrinogen level 
after 90 min was below 1 g/liter in 13% of the patients treated 
with 70 mg of rt-PA. In the urokinase-treated group, 70% of 
the patients had a fibrinogen level of <l g/liter at 90 min. 
Discussion 
Patency of infarct-related artery. The increased infusion 
rate of rt-PA evidently resulted in faster thrombolysis and a 
higher rate of early reperfusion of thrombotic coronary 
occlusion in myocardial infarction. In this study, the patency 
rate of infarct-related coronary arteries was 91% (95% con- 
fidence interval, 82% to 96%) 90 min after the start of 
infusion (5-l 1,12). Because this was an uncontrolled clinical 
study, the patency rates have to be interpreted with caution. 
In an attempt to avoid overestimation of the efficacy of this 
dose regimen, 6 of the 80 patients were excluded from the 
final angiographic analysis, mostly because of borderline ST 
segment elevations in the qualifying ECG. Data analysis on 
the basis of intention to treat leads to even higher patency 
rates (75% at 60 min and 91% at 90 min). 
In some previous studies, the total administered dose of 
r&PA was higher, but the dose infused within 90 min was 
lower than in this study. The higher efficacy of the increased 
infusion rate with a larger initial bolus (15 mg) can be 
explained by the direct relation between dose and throm- 
bolytically effective plasma levels (12). The high initial 
plasma levels resulted in the high patency rate of 74% as 
early as 60 min after the start of infusion, with 59% of vessels 
showing complete reperfusion (TIM1 grade 3). 
The comparison of patency rates of different studies 
requires a comparable study design, especially with respect 
to the time of angiography. In the GAUS study (6), with an 
identical angiographic protocol at 90 min, the patency rate 
was only 69%. In that study rt-PA was given in a dose of 70 
mg over 90 min, which corresponds to the 90 min dose of the 
currently recommended 100 mg of rt-PA over 3 h. The 90 
min patency rate of 75% in the Treatment of Acute Myocar- 
dial Infarction (TAMI) study (811) with a cumulative dose 
between 70 and 85 mg over 90 min was also lower than 
reported here. Patency rates after 3 h or even later may be 
similar for all these dose regimens; however, this question 
cannot be answered from available data. 
The fact that no angiography was performed before the 
initiation of thrombolysis is of little importance if the pa- 
tency rate is high. Assuming a 20% rate of vessels not totally 
occluded initially, the reperfusion rate has to be as high as 
87.5% to lead to a patency rate of 90%. 
The primary goal of fibrinolytic therapy in acute myocar- 
dial infarction, namely, lysis of the occluding coronary 
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thrombus, can be achieved with intravenous administration 
of r&PA at the dose schedule described here in the same 
percentage of patients as with intracoronary thrombolysis in 
combination with mechanical recanalization (14). A further 
significant increase of patency rate achieved with thrombol- 
ysis is unlikely, since in the remaining cases the occlusion of 
the infarct-related coronary artery may not be of thrombotic 
origin (15). 
randomized study comparing this regimen with other more 
widely used regimens of thrombolytic treatment. 
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